ADAR1 Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

ADAR1 Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.96M	Buy	421,787 +90,006	+27%	+$852K	0.18%	112
2026 Q1	$3.12M	Buy	331,781 +45,000	+16%	+$379K	0.18%	106
2025 Q4	$2.33M	Buy	286,781 +276,581	+2,712%	+$3.41M	0.17%	92
2025 Q3	$129K	Buy	+10,200	New	+$97K	0.01%	196
2024 Q4	–	Sell	-4,000	Closed	-$82.5K	–	238
2024 Q3	$82.5K	Sell	4,000 -8,000	-67%	-$409K	0.01%	195
2024 Q2	$543K	Sell	12,000 -4,000	-25%	-$168K	0.1%	95
2024 Q1	$628K	Buy	+16,000	New	+$395K	0.14%	74

Other funds holding CRBP

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

ADAR1 Capital Management's CRBP Position: Q2 2026 in Review

ADAR1 Capital Management increased its Corbus Pharmaceuticals (CRBP) stake by 27% in Q2 2026, buying an estimated $852K and bringing the position to 421,787 shares worth $3.96M. The position accounts for 0.18% of the portfolio, ranked #112.

ADAR1 Capital Management first reported a position in CRBP in Q1 2024 and has held it in 7 quarters since. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

ADAR1 Capital Management held 421,787 shares of Corbus Pharmaceuticals worth $3.96M as of Q2 2026.
ADAR1 Capital Management bought 90,006 Corbus Pharmaceuticals shares in Q2 2026, an estimated $852K.
Corbus Pharmaceuticals made up 0.18% of ADAR1 Capital Management's portfolio in Q2 2026, its #112 holding.
ADAR1 Capital Management first reported a position in Corbus Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.